1
Bender Steven Lee, Broka Chris Allen, Campbell Jeffrey Allen, Castelhano Arlindo Lucas, Fisher Lawrence Emerson, Hendricks Robert Than, Sarma Keshab: Matrix metalloprotease inhibitors. Hoffmann La Roche, Agouron Pharma, June 25, 1997: EP0780386-A1 (167 worldwide citation)

Compounds of the formula: wherein: n is 0, 1 or 2; Y is hydroxy or XONH-, where X is hydrogen or lower alkyl; R is hydrogen or lower alkyl; R is hydrogen, lower alkyl, heteroalkyl, aryl, aralkyl, arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocy ...


2
Dack Kevin Neil, Whitlock Gavin Alistair: Metalloprotease inhibitors. Pfizer, Pfizer, July 28, 1999: EP0931788-A2 (76 worldwide citation)

Compounds of formula (I): where the substituents are as defined herein, and salts thereof, are matrix metalloprotease inhibitors.


3
Richard E Galardy, Damian Grobelny: Matrix metalloprotease inhibitors. Kate N Murashige, Gregory J Giotta, February 2, 1993: US05183900 (39 worldwide citation)

Compounds of the formulas ##STR1## wherein R.sup.1 is H and R.sup.2 is alkyl (3-8C) or wherein R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.n -- wherein n=3-5;


4
Richard E Galardy, Damian Grobelny: Matrix metalloprotease inhibitors. Kate H Murashige, Gregory J Giotta, Felissa H Cagan, February 23, 1993: US05189178 (36 worldwide citation)

Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;


5
Bruce Levin: Methods and compositions for treatment of inflammatory disease. Bruce Levin, Kenyon & Kenyon, January 13, 2004: US06677321 (35 worldwide citation)

Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-infla ...


6
Peter Duncan Brown, Lindsay Jayne Bawden, Karen Margrete Miller: Use of MMP inhibitors. British Biotech Pharmaceuticals, Hale and Dorr, February 16, 1999: US05872152 (30 worldwide citation)

Various known compounds which are matrix metalloprotease inhibitors have been found to be useful in the preparation of agents for promoting tumour regression and/or inhibiting cancer cell proliferation.


7
Richard E Galardy, Damian Grobelny, John H Musser: Matrix metalloprotease inhibitors. Glycomed Incorporated, Kate H Murashige, Gregory J Giotta, August 24, 1993: US05239078 (26 worldwide citation)

Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;


8
Jasbir Singh, Barry A Morgan, James A Gainor, Thomas D Gordon, Robert C Wahl: Succinamide derivative matrix-metalloprotease inhibitors. Sterling Winthrop, Liza D Hohenschutz, October 26, 1993: US05256657 (26 worldwide citation)

Compounds having the structural formula ##STR1## wherein X is HONH or HO and especially wherein the carbon atom bearing CH.sub.2 R.sup.1 has the R-configuration, the carbon atom bearing CH.sub.2 R.sup.2 has the S-configuration, R.sup.1 is isopropyl, R.sup.2 is 3-indolyl, m is 2, n is 0, p is 2 and R ...


9
Richard E Galardy: Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors. Felissa H Cagan, Gregory J Giotta, December 7, 1993: US05268384 (23 worldwide citation)

Synthetic mammalian matrix metalloprotease inhibitors are useful in controlling angiogenesis. These compounds are thus useful in controlling the growth of tumors and in controlling neovascular glaucomas.


10
Daniel E Levy, Damian Grobelny, Cho Tang, Kevin R Holme, Richard E Galardy, Gregory S Schultz, Asaad Nematalia, John H Musser: Process for preparing synthetic matrix metalloprotease inhibitors. Glycomed Incorporated, The University of Florida, Lyon & Lyon, April 6, 1999: US05892112 (22 worldwide citation)

Synthetic mammalian matrix metalloprotease inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian matrix metalloprotease activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, an ...